Osteoporosis, bone & mineral

Phenotypic Profiling and Molecular Mechanisms in Hyperparathyroidism-jaw Tumor Syndrome

J Clin Endocrinol MetabPublished Retrospective cohort study

Authors' conclusion

Multiple, recurrent atypical adenomyomatous uterine polyps appear to be enriched in women with HPT-JT and appear characteristic of the disease. Patients with CDC73 variants at p.M1 residue appear predisposed to kidney tumors.

Study context

Population
Patients with hyperparathyroidism-jaw tumor (HPT-JT) syndrome (genetically confirmed or affected first-degree relatives), 29 kindreds; median age at last follow-up 39 [IQR, 29–53] years29 kindreds
Participants
68 patients
Outcome
Natural history of HPT-JT
Methodological detailsparafibromin immunostaining, RNA-sequencing
  • Parafibromin immunostaining
  • RNA-sequencing

Main finding

As reported in the abstract

Developed PHPT
55/68 (81%)
Parathyroid carcinoma among those with PHPT
17/55 (31%)
Females with uterine tumors
12 of 32 (38%)
Resected uterine tumors that were rare mixed epithelial mesenchymal polypoid lesions (11 patients)
12/24 (50%)
Solid kidney tumors
4 of 68 (6%)
Kidney tumor patients with CDC73 variant at p.M1 residue
3/4

Observational data: associations, not effects.

Further findings

Parafibromin staining of parathyroid tumors (19 patients: 13 adenomas, 6 carcinomas)

Parafibromin staining did not correlate with tumor histology or genotype

RNA-sequencing of 21 parathyroid samples (8 HPT-JT adenomas, 6 HPT-JT carcinomas, 7 sporadic carcinomas with wild-type CDC73)

HPT-JT-related parathyroid tumors significantly associated with transmembrane receptor protein tyrosine kinase signaling, mesodermal commitment pathway and cell-cell adhesion

Original publication

Phenotypic Profiling and Molecular Mechanisms in Hyperparathyroidism-jaw Tumor Syndrome. J Clin Endocrinol Metab. Published 20 June 2023. doi:10.1210/clinem/dgad368

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.